Serious infections caused by methicillin-resistant Staphylococcus aureus

Helen Boucher, Loren G. Miller, Raymund R Razonable

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Although first identified just >4 decades ago, methicillin-resistant Staphylococcus aureus (MRSA) has undergone rapid evolutionary changes and epidemiologic expansion to become a major cause of nosocomial and community-acquired infections worldwide. Increasing resistance to vancomycin among MRSA strains in conjunction with availability of new antibiotics, including daptomycin and linezolid, have increased treatment choices but made clinical treatment decisions more challenging. This article describes the clinical features and management issues of 2 challenging-to-treat manifestations of MRSA infection, bacteremia and/or endocarditis and osteomyelitis. It also presents a brief review of community-associated MRSA infections and preventive strategies directed against MRSA.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume51
Issue numberSUPPL. 2
DOIs
StatePublished - Sep 15 2010

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Infection
Linezolid
Vancomycin Resistance
Daptomycin
Community-Acquired Infections
Osteomyelitis
Bacteremia
Endocarditis
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Serious infections caused by methicillin-resistant Staphylococcus aureus. / Boucher, Helen; Miller, Loren G.; Razonable, Raymund R.

In: Clinical Infectious Diseases, Vol. 51, No. SUPPL. 2, 15.09.2010.

Research output: Contribution to journalArticle

@article{bec2bc5fdce143db9e9f05e1a314cf83,
title = "Serious infections caused by methicillin-resistant Staphylococcus aureus",
abstract = "Although first identified just >4 decades ago, methicillin-resistant Staphylococcus aureus (MRSA) has undergone rapid evolutionary changes and epidemiologic expansion to become a major cause of nosocomial and community-acquired infections worldwide. Increasing resistance to vancomycin among MRSA strains in conjunction with availability of new antibiotics, including daptomycin and linezolid, have increased treatment choices but made clinical treatment decisions more challenging. This article describes the clinical features and management issues of 2 challenging-to-treat manifestations of MRSA infection, bacteremia and/or endocarditis and osteomyelitis. It also presents a brief review of community-associated MRSA infections and preventive strategies directed against MRSA.",
author = "Helen Boucher and Miller, {Loren G.} and Razonable, {Raymund R}",
year = "2010",
month = "9",
day = "15",
doi = "10.1086/653519",
language = "English (US)",
volume = "51",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Serious infections caused by methicillin-resistant Staphylococcus aureus

AU - Boucher, Helen

AU - Miller, Loren G.

AU - Razonable, Raymund R

PY - 2010/9/15

Y1 - 2010/9/15

N2 - Although first identified just >4 decades ago, methicillin-resistant Staphylococcus aureus (MRSA) has undergone rapid evolutionary changes and epidemiologic expansion to become a major cause of nosocomial and community-acquired infections worldwide. Increasing resistance to vancomycin among MRSA strains in conjunction with availability of new antibiotics, including daptomycin and linezolid, have increased treatment choices but made clinical treatment decisions more challenging. This article describes the clinical features and management issues of 2 challenging-to-treat manifestations of MRSA infection, bacteremia and/or endocarditis and osteomyelitis. It also presents a brief review of community-associated MRSA infections and preventive strategies directed against MRSA.

AB - Although first identified just >4 decades ago, methicillin-resistant Staphylococcus aureus (MRSA) has undergone rapid evolutionary changes and epidemiologic expansion to become a major cause of nosocomial and community-acquired infections worldwide. Increasing resistance to vancomycin among MRSA strains in conjunction with availability of new antibiotics, including daptomycin and linezolid, have increased treatment choices but made clinical treatment decisions more challenging. This article describes the clinical features and management issues of 2 challenging-to-treat manifestations of MRSA infection, bacteremia and/or endocarditis and osteomyelitis. It also presents a brief review of community-associated MRSA infections and preventive strategies directed against MRSA.

UR - http://www.scopus.com/inward/record.url?scp=77957868388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957868388&partnerID=8YFLogxK

U2 - 10.1086/653519

DO - 10.1086/653519

M3 - Article

C2 - 20731576

AN - SCOPUS:77957868388

VL - 51

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 2

ER -